To reflect how common cold sufferers experiencing a blocked nose use xylometazoline nasal spray in everyday life, a fully decentralized, longitudinal, real-world, open-label study design was chosen. The study was the first to demonstrate the effectiveness of a nasal decongestant on the common cold to improve QoL factors. WURSS-21 total score and total symptom score improved significantly from moderate to mild severity by day 2 of the study, whereas the WURSS-21 total QoL score significantly improved from day 1. These results suggest that although participants were still experiencing moderate symptoms, nasal decongestion may have helped them to resume their daily living at an earlier stage of the common cold compared with the natural course of the disease.